CN111011866A - Application of prebiotics in promoting growth of lactobacillus plantarum in intestinal environment - Google Patents
Application of prebiotics in promoting growth of lactobacillus plantarum in intestinal environment Download PDFInfo
- Publication number
- CN111011866A CN111011866A CN201911271422.1A CN201911271422A CN111011866A CN 111011866 A CN111011866 A CN 111011866A CN 201911271422 A CN201911271422 A CN 201911271422A CN 111011866 A CN111011866 A CN 111011866A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- prebiotics
- growth
- promoting
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 85
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 85
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 85
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 68
- 230000012010 growth Effects 0.000 title claims abstract description 60
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 25
- 230000001737 promoting effect Effects 0.000 title claims abstract description 24
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 26
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 20
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 18
- 238000000855 fermentation Methods 0.000 claims abstract description 13
- 230000004151 fermentation Effects 0.000 claims abstract description 12
- 230000035755 proliferation Effects 0.000 claims abstract description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract description 16
- 229940107187 fructooligosaccharide Drugs 0.000 abstract description 14
- 244000005700 microbiome Species 0.000 abstract description 4
- 239000011159 matrix material Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 23
- 229910052799 carbon Inorganic materials 0.000 description 23
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 229920001202 Inulin Polymers 0.000 description 10
- 229940029339 inulin Drugs 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000034655 secondary growth Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- -1 diamine citrate Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides application of prebiotics in promoting growth of lactobacillus plantarum in an intestinal environment, and belongs to the field of microorganisms. The invention provides an application of fructo-oligosaccharide or galacto-oligosaccharide in promoting growth of lactobacillus plantarum AR237 in an intestinal environment, and also provides an application of isomaltooligosaccharide in promoting proliferation of lactobacillus plantarum AR113 or lactobacillus plantarum AR237 in a middle fermentation stage. Not all prebiotics have a proliferation promoting effect on lactobacillus plantarum in the middle of fermentation, and some prebiotics also have a matrix inhibiting effect.
Description
Technical Field
The invention relates to application of prebiotics in promoting growth of lactobacillus plantarum in an intestinal environment, and belongs to the field of microorganisms.
Background
The prebiotics are difficult to be absorbed and utilized by human intestinal tracts, but can be selectively utilized by microorganisms as nutrient components, and can improve the metabolism of the probiotics and promote the growth and reproduction of the probiotics. Due to the important role of the micro-ecological environment of human intestinal microorganisms, prebiotics and probiotics are at the focus of research and many correlation studies are being carried out around them.
The lactobacillus plantarum is one of lactobacillus, has the optimal growth temperature of 30-35 ℃, is anaerobic or facultative anaerobic, has straight or bent rod-shaped strains, is single or sometimes paired or chain-shaped, has the optimal pH of about 6.5, belongs to homofermentation lactobacillus, has a plurality of health-care functions, such as ① having certain immunoregulation function, ② having inhibition effect on pathogenic bacteria, ③ reducing serum cholesterol content and preventing cardiovascular diseases, ④ maintaining the balance of intestinal flora, ⑤ promoting nutrient absorption, ⑥ relieving lactose intolerance, ⑦ inhibiting the formation of tumor cells, and the like.
However, because different probiotics have extremely strong strain specificity, the utilization of prebiotics by different probiotics and even by different probiotic strains of the same species is different. In the prior art, the study of the lactobacillus plantarum on the utilization of the prebiotics is lacked, and particularly the study of the lactobacillus plantarum on the utilization of the prebiotics in the intestinal environment is lacked. Through research on the utilization of the lactobacillus plantarum on the prebiotics in the intestinal environment, people can develop lactic acid bacteria beverage or food which has higher nutritional value and can condition the intestines and stomach of a human body.
Disclosure of Invention
The present invention has been made to solve the above problems, and an object of the present invention is to provide a use of prebiotics for promoting the growth of lactobacillus plantarum in an intestinal environment.
The invention provides an application of prebiotics in promoting the growth of lactobacillus plantarum in an intestinal environment, which has the characteristics that: the prebiotics are fructo-oligosaccharide or galacto-oligosaccharide.
In the application of the prebiotics provided by the invention in promoting the growth of lactobacillus plantarum in an intestinal environment, the prebiotics can also have the following characteristics: wherein the lactobacillus plantarum is lactobacillus plantarum AR 237.
In the application of the prebiotics provided by the invention in promoting the growth of lactobacillus plantarum in an intestinal environment, the prebiotics can also have the following characteristics: wherein the concentration of the prebiotics is 10 mug/mL-30 mug/mL.
The invention also provides application of isomaltose hypgather in promoting proliferation of lactobacillus plantarum in the middle stage of fermentation.
In the application of the isomaltooligosaccharide provided by the invention in promoting the proliferation of lactobacillus plantarum in the middle stage of fermentation, the isomaltooligosaccharide also has the following characteristics: wherein the concentration of isomaltooligosaccharide is 10. mu.g/mL-30. mu.g/mL.
In the application of the isomaltooligosaccharide provided by the invention in promoting the proliferation of lactobacillus plantarum in the middle stage of fermentation, the isomaltooligosaccharide also has the following characteristics: wherein the Lactobacillus plantarum is Lactobacillus plantarum AR113 or Lactobacillus plantarum AR 237.
Action and Effect of the invention
According to the application of the prebiotics in the intestinal environment to promote the growth of the lactobacillus plantarum, the fructo-oligosaccharides and the galactooligosaccharides can be absorbed and utilized by specific lactobacillus plantarum strains in the intestinal microenvironment better, so that the number of specific lactobacillus plantarum is increased remarkably within a certain time, and therefore the fructo-oligosaccharides and the galactooligosaccharides provided by the invention can promote the growth of the specific lactobacillus plantarum.
Drawings
FIG. 1 is a graph of the growth of Lactobacillus plantarum AR113 in a medium with different prebiotics as carbon source in an example of the invention;
FIG. 2 is a graph of the growth of Lactobacillus plantarum AR117 in a medium with different prebiotics as carbon source in an example of the invention;
FIG. 3 is a graph of the growth of Lactobacillus plantarum AR237 in a medium with different prebiotics as carbon source in an example of the invention;
FIG. 4 is a graph of the growth of Lactobacillus plantarum AR509 in a medium with different prebiotics as carbon source in an example of the invention;
FIG. 5 is a graph of the growth of Lactobacillus plantarum AR514 in a medium with different prebiotics as carbon source in an example of the invention;
FIG. 6 is a graph of the growth of Lactobacillus plantarum AR113 in a simulated mouse gut environment with different prebiotics in an example of the invention;
FIG. 7 is a graph of the growth of Lactobacillus plantarum AR113 in a simulated mouse gut environment with different prebiotics in an example of the invention;
FIG. 8 is a graph of the growth of Lactobacillus plantarum AR113 in a simulated mouse gut environment with different prebiotics in an example of the invention;
FIG. 9 is a graph of the growth of Lactobacillus plantarum AR113 in a simulated mouse gut environment with different prebiotics in an example of the invention;
fig. 10 is a graph of the growth of lactobacillus plantarum AR113 in a simulated mouse gut environment with different prebiotics in an example of the invention.
Detailed Description
In order to make the technical means, the creation features, the achievement purposes and the effects of the invention easy to understand, the invention is specifically described below by combining the embodiment and the attached drawings.
Specifically, the sources of the raw materials used in the following examples are as follows:
lactobacillus plantarum AR113 strain has been deposited in China general microbiological culture Collection center (address: No. 3, Xilu No.1, Beijing, Chaoyang, North Cheng) in 2017, 03, 22 and 22 months, and its number is CGMCC No. 13909.
Lactobacillus plantarum AR237 strain has been deposited in the China general microbiological culture Collection center (address: No. 3, Xilu No.1, Beijing, the south China, north China) on 04.07.2017, and the number is CGMCC No. 14003.
The Lactobacillus plantarum (Lactobacillus plantarum) AR117 strain, the Lactobacillus plantarum (Lactobacillus plantarum) AR509 strain and the Lactobacillus plantarum (Lactobacillus plantarum) AR514 strain are obtained by self-screening in a laboratory by the inventors.
MRS culture medium formula: 10.0g of peptone, 2.0g of dipotassium phosphate, 10.0g of beef extract powder, 5.0g of yeast extract, 0.25g of manganese sulfate, 5.0g of anhydrous sodium acetate, 20.0g of glucose, 2.0g of diamine citrate, 0.58g of magnesium sulfate, Tween-801mL and 1000mL of deionized water.
< example >
Experiments are carried out by taking lactobacillus plantarum AR113, AR117, AR237, AR509 and AR514 as research objects, and the specific steps are as follows:
the specific experimental procedure is as follows:
five strains (AR113, AR117, AR237, AR509 and AR514) are taken out from a refrigerator at the temperature of-80 ℃, streaked on an MRS solid medium, cultured and activated in an anaerobic incubator for 48 hours, and preserved by a glycerol preservation method after being repeated three times for standby.
The five activated strains are inoculated into an MRS culture medium according to the inoculation amount of 1 percent, 2 percent of the prebiotics (namely 20ug/ml FOS, 20ug/ml XOS, 20ug/ml GOS, 20ug/ml IMO and 20ug/ml Inulin) are respectively added into each strain culture medium, wherein the added prebiotics are filtered by a 0.22um water phase filter to keep the added prebiotics in a sterile state, no prebiotics are added into a Control group (Control), and the OD value of the strain at 600nm is measured by using a growth curve instrument.
The results of the experiment are shown in table 1.
TABLE 1 absorbance values of Lactobacillus plantarum in MRS media supplemented with different prebiotics
As shown in Table 1, after different 20. mu.g/ml prebiotics are added to the MRS culture medium, IMO has obvious promotion effect on each Lactobacillus plantarum in the middle stage of culture. Five lactobacillus plantarum strains have obvious difference of absorbance between an IMO group and a control group (P <0.05) at 24h and 32h, while other prebiotic groups have no obvious proliferation effect on the strains, and the growth state of some prebiotic groups is obviously inhibited compared with the control group (P <0.05) due to the change of the substrate concentration, such as an FOS group of AR113, an XOS group of XOS, an INULIN group of AR117, an XOS group and GOS group of AR237, an FOS group of AR509, an XOS group, an INULin group, an XOS group of AR514, a GOS group and an InULin group. In the five strains, except for the IMO groups of AR113, AR509 and AR514, the secondary growth phenomenon occurs in the late stage of fermentation culture, and the secondary growth phenomenon does not occur in the IMO groups of the five strains. This is probably because when glucose and isomaltose hypgather are used as the composite carbon source, lactobacillus plantarum can be simultaneously absorbed and utilized to promote the growth and propagation of the strain, and after other prebiotics are compounded with glucose, the strain preferentially utilizes glucose as the carbon source to generate catabolite repression effect. Therefore the direct addition of prebiotics in MRS medium cannot be used as a screen for prebiotics suitable for lactobacillus plantarum.
And 2, replacing glucose in the MRS culture medium with the prebiotics in the step 1, culturing the lactobacillus plantarum by using the prebiotics as a carbon source, and determining a growth curve.
The specific experimental steps are as follows:
MRS basic culture medium without glucose is prepared, 2% of prebiotics (namely 20ug/ml FOS, 20ug/ml XOS, 20ug/ml GOS, 20ug/ml IMO and 20ug/ml Inulin) are used for replacing glucose as carbon source, five activated lactobacillus plantarum strains are inoculated into the basic culture medium in the inoculation amount of 1%, and the absorbance at 600nm is measured by using a growth curve instrument and a growth curve is drawn.
The test results are shown in FIGS. 1-5.
FIG. 1 is a graph of the growth of Lactobacillus plantarum AR113 in a medium with different prebiotics as carbon source in an example of the invention. FIG. 2 is a graph showing the growth of Lactobacillus plantarum AR117 in media with different prebiotics as carbon sources in examples of the present invention. FIG. 3 is a graph showing the growth of Lactobacillus plantarum AR237 in a medium with different prebiotics as carbon source in examples of the present invention. FIG. 4 is a graph showing the growth of Lactobacillus plantarum AR509 in a medium with different prebiotics as carbon source in an example of the present invention. FIG. 5 is a graph showing the growth of Lactobacillus plantarum AR514 in a medium with different prebiotics as carbon source in an example of the present invention.
As shown in FIGS. 1-5, the absorption and utilization of FOS, GOS and IMO by AR113 are good, the growth is very vigorous, the growth is second to Inulin, and the growth is very slow when XOS is used as a carbon source; AR117 has good growth condition in MRS culture medium with FOS and GOS as carbon source, IMO and Inulin are inferior, and XOS has poor growth condition; AR237 has good growth condition in MRS culture medium with FOS and Inulin as carbon sources, IMO and GOS are inferior, and XOS has poor growth condition; AR509 has good growth condition in MRS culture medium taking FOS and GOS as carbon sources, IMO is inferior, and growth condition of Inulin and XOS is poor; AR514 grows well in MRS medium with Inulin and FOS as carbon source, and the growth conditions of GOS, IMO and XOS are inferior. 2 kinds of suitable prebiotics are screened out for each lactobacillus plantarum to continue the experiment by integrating the growth conditions of each strain. Therefore, the addition of prebiotics in MRS medium without glucose can be used as a screen for prebiotics suitable for the growth of Lactobacillus plantarum.
And 3, simulating the intestinal environment of the mouse in vitro, performing liquid culture on different lactobacillus plantarum by using the sterilized excrement of the mouse and the prebiotics obtained by screening, and drawing a growth curve, thereby exploring the absorption effect of the lactobacillus plantarum on the prebiotics in the simulated intestinal environment.
The specific experimental steps are as follows: preparing a liquid culture medium of mouse feces: 6ug/ml mouse feces +20ug/ml tryptone. According to the experimental result of the step 2, two kinds of prebiotics with good absorption effect of each strain are selected, the activated bacteria liquid is centrifuged at 9600rpm for 1min, supernatant liquid is poured out, the bacteria liquid is washed by sterile water and then inoculated into a liquid culture medium of the mouse excrement with the inoculation amount of 1%, corresponding prebiotics are respectively added, the concentration is 1%, namely 10ug/ml, and the instrument measures the absorbance at 600nm and then draws the growth curve. The specific grouping of step 3 is shown in table 2.
TABLE 2 Experimental design groupings
The results of the experiments are shown in FIGS. 6-10.
As shown in fig. 6 to 10, when each lactobacillus plantarum was fermented in vitro in a mouse feces liquid medium, the growth conditions of each strain were greatly different from those in the MRS medium due to changes in the nutrient composition. Although the number of bacteria was significantly reduced in the fermentation process, AR113 and AR509 had good growth conditions and could absorb FOS and GOS as carbon sources. AR117 grew slower than AR113 and AR509 and did not adapt well to the simulated mouse intestinal environment. AR237 and AR514 grew well when FOS was used as a carbon source, and were similar to AR113 and AR509, while when Inulin was used as a carbon source, the effect of absorption and utilization was significantly reduced compared to the case of the medium in MRS (FIG. 3 and FIG. 5).
In conclusion, IMO has the effect of promoting the proliferation of lactobacillus in each plant in the middle stage of fermentation at the concentration level of 20 ug/ml. While other prebiotics can not play a role in promoting growth of the lactobacillus plantarum at the concentration level of 20ug/ml, and some prebiotics also cause the effect of matrix inhibition. Among five lactobacillus plantarum strains, AR117 has weak adaptability to simulated intestinal environments, and the other four strains have strong adaptability. Of the five prebiotics, FOS and GOS can be absorbed and utilized by the strain in the intestinal microenvironment better, and the growth of the strain is promoted.
Effects and effects of the embodiments
According to the application of the prebiotics in the intestinal environment to promote the growth of lactobacillus plantarum, the provided fructo-oligosaccharides and galacto-oligosaccharides can promote the growth of specific lactobacillus plantarum because the fructo-oligosaccharides and the galacto-oligosaccharides can be absorbed and utilized by specific lactobacillus plantarum strains in the intestinal microenvironment better, so that the number of specific lactobacillus plantarum is increased remarkably within a certain time.
According to the application of isomaltooligosaccharide in promoting proliferation of lactobacillus plantarum in the middle fermentation stage, when glucose and isomaltooligosaccharide are used as a composite carbon source, lactobacillus plantarum can be absorbed and utilized simultaneously to promote growth and propagation of strains, the lactobacillus plantarum has the function of promoting proliferation in the middle fermentation stage, other prebiotics cannot play an obvious role in promoting growth of lactobacillus plantarum at the same concentration level, and some prebiotics also cause a matrix inhibition effect.
The above embodiments are preferred examples of the present invention, and are not intended to limit the scope of the present invention.
Claims (6)
1. The application of prebiotics in promoting the growth of lactobacillus plantarum in an intestinal environment is characterized in that the prebiotics are fructo-oligosaccharides or galacto-oligosaccharides.
2. Use of prebiotics according to claim 1 to promote the growth of Lactobacillus plantarum in an intestinal environment, characterized in that:
wherein the lactobacillus plantarum is lactobacillus plantarum AR 237.
3. Use of prebiotics according to claim 1 to promote the growth of Lactobacillus plantarum in an intestinal environment, characterized in that:
wherein the concentration of the prebiotics is 10 mug/mL-30 mug/mL.
4. The application of isomaltose hypgather in promoting the proliferation of lactobacillus plantarum in the middle stage of fermentation.
5. Use of isomaltooligosaccharides according to claim 4 for promoting proliferation of Lactobacillus plantarum in mid-fermentation stage, characterized in that:
wherein the concentration of the isomaltooligosaccharide is 10 to 30. mu.g/mL.
6. The use of isomaltooligosaccharides according to claim 4 for promoting proliferation of Lactobacillus plantarum in the middle stage of fermentation,
wherein the lactobacillus plantarum is lactobacillus plantarum AR113 or lactobacillus plantarum AR 237.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911271422.1A CN111011866B (en) | 2019-12-12 | 2019-12-12 | Application of prebiotics in promoting growth of lactobacillus plantarum in intestinal environment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911271422.1A CN111011866B (en) | 2019-12-12 | 2019-12-12 | Application of prebiotics in promoting growth of lactobacillus plantarum in intestinal environment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111011866A true CN111011866A (en) | 2020-04-17 |
| CN111011866B CN111011866B (en) | 2023-03-24 |
Family
ID=70208824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911271422.1A Active CN111011866B (en) | 2019-12-12 | 2019-12-12 | Application of prebiotics in promoting growth of lactobacillus plantarum in intestinal environment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111011866B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111304134A (en) * | 2020-03-26 | 2020-06-19 | 上海理工大学 | Lactobacillus plantarum capable of effectively relieving diabetes |
| CN112553118A (en) * | 2020-12-24 | 2021-03-26 | 上海理工大学 | Method for enriching beneficial bacteria by using prebiotics |
| CN113812634A (en) * | 2021-09-22 | 2021-12-21 | 深圳市华大农业应用研究院 | Synbiotic composition and preparation method and application thereof |
| CN114262680A (en) * | 2022-01-04 | 2022-04-01 | 澳优乳业（中国）有限公司 | Bacterial strain and application thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101559082A (en) * | 2009-06-01 | 2009-10-21 | 天津科技大学 | Method for preparing probiotic preparation for reducing blood lipid and adjusting intestinal flora |
| CN102524391A (en) * | 2010-12-21 | 2012-07-04 | 内蒙古蒙牛乳业（集团）股份有限公司 | Fermented dairy product containing compound prebiotic and probiotic group |
| CN105011151A (en) * | 2015-05-25 | 2015-11-04 | 华隆（乳山）食品工业有限公司 | Composite prebiotics capable of regulating intestinal tract function of human body |
| CN105831245A (en) * | 2016-04-14 | 2016-08-10 | 浙江大学宁波理工学院 | Flavored symbiotic fermented milk and manufacturing method thereof |
| CN106819107A (en) * | 2016-12-29 | 2017-06-13 | 石家庄君乐宝乳业有限公司 | Leben with the effect of whole intestines and preparation method thereof |
| CN108384821A (en) * | 2017-12-18 | 2018-08-10 | 江苏省农业科学院 | A kind of preparation method of the oligosaccharide of promotion proliferation of intestinal probiotics |
| CN108611297A (en) * | 2018-05-03 | 2018-10-02 | 上海理工大学 | A kind of lactobacillus plantarum improving bone calcium phosphorus content |
| CN108795809A (en) * | 2018-06-19 | 2018-11-13 | 山东中科嘉亿生物工程有限公司 | Product and the application of a kind of lactobacillus plantarum JYLP-002 and its preparation |
| CN109601620A (en) * | 2018-11-21 | 2019-04-12 | 石家庄君乐宝乳业有限公司 | Acidified milk and preparation method thereof containing lactobacillus plantarum N3117 |
| CN109619595A (en) * | 2018-12-27 | 2019-04-16 | 天津活力达生物科技有限公司 | A kind of composition and its application containing profitable probliotics and prebiotics |
| CN110387330A (en) * | 2019-07-17 | 2019-10-29 | 上海理工大学 | The freeze-drying method of lactobacillus plantarum survival rate is improved using composite protectant |
-
2019
- 2019-12-12 CN CN201911271422.1A patent/CN111011866B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101559082A (en) * | 2009-06-01 | 2009-10-21 | 天津科技大学 | Method for preparing probiotic preparation for reducing blood lipid and adjusting intestinal flora |
| CN102524391A (en) * | 2010-12-21 | 2012-07-04 | 内蒙古蒙牛乳业（集团）股份有限公司 | Fermented dairy product containing compound prebiotic and probiotic group |
| CN105011151A (en) * | 2015-05-25 | 2015-11-04 | 华隆（乳山）食品工业有限公司 | Composite prebiotics capable of regulating intestinal tract function of human body |
| CN105831245A (en) * | 2016-04-14 | 2016-08-10 | 浙江大学宁波理工学院 | Flavored symbiotic fermented milk and manufacturing method thereof |
| CN106819107A (en) * | 2016-12-29 | 2017-06-13 | 石家庄君乐宝乳业有限公司 | Leben with the effect of whole intestines and preparation method thereof |
| CN108384821A (en) * | 2017-12-18 | 2018-08-10 | 江苏省农业科学院 | A kind of preparation method of the oligosaccharide of promotion proliferation of intestinal probiotics |
| CN108611297A (en) * | 2018-05-03 | 2018-10-02 | 上海理工大学 | A kind of lactobacillus plantarum improving bone calcium phosphorus content |
| CN108795809A (en) * | 2018-06-19 | 2018-11-13 | 山东中科嘉亿生物工程有限公司 | Product and the application of a kind of lactobacillus plantarum JYLP-002 and its preparation |
| CN109601620A (en) * | 2018-11-21 | 2019-04-12 | 石家庄君乐宝乳业有限公司 | Acidified milk and preparation method thereof containing lactobacillus plantarum N3117 |
| CN109619595A (en) * | 2018-12-27 | 2019-04-16 | 天津活力达生物科技有限公司 | A kind of composition and its application containing profitable probliotics and prebiotics |
| CN110387330A (en) * | 2019-07-17 | 2019-10-29 | 上海理工大学 | The freeze-drying method of lactobacillus plantarum survival rate is improved using composite protectant |
Non-Patent Citations (4)
| Title |
|---|
| 孔璐等: "外源乳酸菌对低聚异麦芽糖肠道发酵产酸的影响", 《中国食品学报》 * |
| 孙思睿等: "低聚半乳糖对植物乳杆菌生长及部分代谢的影响", 《食品工业科技》 * |
| 杨郁等: "低聚糖对植物乳杆菌XC-10的影响研究", 《现代农业科技》 * |
| 武香玉等: "不同益生元对肠道菌群的影响", 《饲料博览》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111304134A (en) * | 2020-03-26 | 2020-06-19 | 上海理工大学 | Lactobacillus plantarum capable of effectively relieving diabetes |
| CN112553118A (en) * | 2020-12-24 | 2021-03-26 | 上海理工大学 | Method for enriching beneficial bacteria by using prebiotics |
| CN113812634A (en) * | 2021-09-22 | 2021-12-21 | 深圳市华大农业应用研究院 | Synbiotic composition and preparation method and application thereof |
| CN114262680A (en) * | 2022-01-04 | 2022-04-01 | 澳优乳业（中国）有限公司 | Bacterial strain and application thereof |
| CN114262680B (en) * | 2022-01-04 | 2023-07-04 | 澳优乳业（中国）有限公司 | Bacterial strain and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111011866B (en) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111011866B (en) | Application of prebiotics in promoting growth of lactobacillus plantarum in intestinal environment | |
| CN110106119B (en) | Lactobacillus rhamnosus M9 separated from breast milk and application thereof | |
| CN103013879B (en) | Bacterial strain having capacity of giving high yield of Gamma-aminobutyric acid | |
| CN106868072A (en) | A kind of preparation method of small-molecular-weight Dendrobium officinale polysaccharide | |
| CN107893044A (en) | One plant of bifidobacterium longum and its application | |
| CN110669697B (en) | Lactobacillus casei for high yield of short-chain fatty acid, culture method and application thereof | |
| CN103114051A (en) | Roy bacterium lacticum and application thereof | |
| WO2022110727A1 (en) | Application of lactobacillus paracasei et-22 in improving intestinal bacterial infection resistance and intestinal immunity | |
| CN102517238B (en) | Acid-producing bacillus cereus and application thereof | |
| CN111500508B (en) | Liquid mixed fermentation method of clostridium butyricum and bacillus coagulans | |
| CN109749957A (en) | A kind of preparation and application of the lactobacillus gasseri preparation with aquatic pathogenic bacterium antagonistic properties | |
| CN101810249A (en) | Method for producing complex-probiotic group by solid fermentation | |
| CN113736683A (en) | Streptococcus thermophilus for inhibiting helicobacter pylori and application thereof | |
| CN115340967B (en) | Alcohol-resistant lactobacillus rhamnosus and application thereof | |
| CN115232768B (en) | Lactobacillus paracasei JN-8 and application thereof | |
| CN116024130A (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
| CN113249244B (en) | Lactobacillus paracasei for antagonizing pharyngitis pathogenic bacteria beta hemolytic streptococcus | |
| CN114642686A (en) | Composite probiotics and anti-aging and anti-oxidation effects thereof | |
| CN112391318B (en) | Preparation method of bifidobacterium longum and selenium-enriched microorganism and preparation method of freeze-dried preparation thereof | |
| CN114262680B (en) | Bacterial strain and application thereof | |
| CN104472854B (en) | A kind of corn ferment for improving content of reducing sugar and its application | |
| CN105624071A (en) | Lactobacillus salivarius XJP2 and application thereof | |
| CN115895966A (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
| Nagpal et al. | Influence of bacteria and protozoa from the rumen of buffalo on in-vitro activities of anaerobic fungus Caecomyces sp. isolated from the feces of elephant | |
| CN113397170B (en) | Application of marine prebiotics composition for regulating human intestinal flora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |